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Background & Aims—Gluteofemoral obesity (determined by measurement of subcutaneous fat 
in hip and thigh regions) could reduce risks of cardiovascular and diabetic disorders associated 
with abdominal obesity. We evaluated whether gluteofemoral obesity also reduces risk of Barrett's 
esophagus (BE), a premalignant lesion associated with abdominal obesity.
Methods—We collected data from non-Hispanic white participants in 8 studies in the Barrett's 
and Esophageal Adenocarcinoma Consortium. We compared measures of hip circumference (as a 
proxy for gluteofemoral obesity) from cases of BE (n=1559) separately with 2 control groups: 
2557 population-based controls and 2064 individuals with gastroesophageal reflux disease (GERD 
controls). Study-specific odds ratios (OR) and 95% confidence intervals (95% CI) were estimated 
using individual participant data and multivariable logistic regression and combined using random 
effects meta-analysis.
Results—We found an inverse relationship between hip circumference and BE (OR per 5 cm 
increase, 0.88; 95% CI, 0.81–0.96), compared with population-based controls in a multivariable 
model that included waist circumference. This association was not observed in models that did not 
include waist circumference. Similar results were observed in analyses stratified by frequency of 
GERD symptoms. The inverse association with hip circumference was only statistically significant 
among men (vs population-based controls: OR, 0.85; 95% CI, 0.76–0.96 for men; OR, 0.93; 95% 
CI, 0.74–1.16 for women). For men, within each category of waist circumference, a larger hip 
circumference was associated with decreased risk of BE. Increasing waist circumference was 
associated with increased risk of BE in the mutually adjusted population-based and GERD control 
models.
Conclusions—Although abdominal obesity is associated with increased risk of BE, there is an 
inverse association between gluteofemoral obesity and BE—particularly among men.
Keywords
BEACON; Obesity; Esophageal Cancer; Epidemiology; Risk Factors
Abdominal obesity is associated with an increased risk of esophageal adenocarcinoma (EA) 
and its precursor lesion Barrett's esophagus (BE).1,2 These associations remain after 
controlling for the confounding effects of gastroesophageal reflux disease (GERD) 
symptoms, suggesting that non-GERD factors are important.3 In abdominal obesity, 
increased intra-abdominal adipose tissue stores may cause a number of systemic effects 
including insulin resistance, alteration in adipokines and cytokines, and systemic chronic 
inflammation.4 These systemic effects have been associated with non-esophageal cancers 
and a recent meta-analysis found they may be important in BE.5
Abdominal obesity is also strongly associated with an increased risk of diabetes mellitus and 
cardiovascular disease.6 In contrast, gluteofemoral obesity, manifested by increased 
subcutaneous fat in the hip and thigh region, has a protective association with these 
disorders.7,8 One postulated mechanism for this protective effect is that gluteofemoral 
adipose tissue acts as a metabolic “sink” reducing the levels of circulating free fatty acids, 
insulin and adipocytokines that lead to metabolic and cardiovascular disease.9
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Few studies have examined the effects of gluteofemoral obesity on the risks of EA and BE. 
A large cohort study of 391,456 participants (of whom 124 developed EA during follow-up) 
found that, after mutual adjustment, the risk of EA was strongly positively associated with 
abdominal obesity but inversely associated with gluteofemoral obesity.10 In a case-control 
study of BE, conducted among males referred for colorectal cancer screening, there was a 
suggestion of a similar inverse association with gluteofemoral obesity, although the 
precision of the estimates were limited by study size and sex-specific effects were unable to 
be analyzed as all participants were males.11
Investigating the effects of fat distribution patterns on the risk of BE is important in 
furthering our understanding of the role of obesity in BE. If gluteofemoral obesity were 
found to reduce the risks associated with abdominal obesity, this would support the 
hypothesis that potentially modifiable metabolic factors related to abdominal obesity (but 
unrelated to GERD) are important in the pathogenesis of the disease. In addition, sex 
differences in fat distribution may help explain the large male-predominance seen at each 
stage of the natural history of EA including BE.12-15
The international Barrett's and Esophageal Adenocarcinoma Consortium (BEACON, http://
beacon.tlvnet.net/) is a large international consortium that has pooled and harmonized 
detailed individual participant data including anthropometric measurements from case-
control studies of BE. Using this unique resource, this analysis determined the risks of BE 
associated with gluteofemoral and abdominal obesity and assessed the effects of each 
exposure after mutual adjustment. Further, we sought to determine if there were sex 
differences in these associations and whether the associations with gluteofemoral and 
abdominal obesity were confounded or modified by other known risk factors for BE.
Materials and Methods
Study population
BEACON was formed in 2005 in collaboration with the US National Cancer Institute. For 
the purpose of this analysis, we initially pooled individual participant data from 1909 BE 
cases, 3618 population-based controls and 2666 GERD controls from eight independent 
case-control studies participating in BEACON (see Supplementary Material)11,16-21. Details 
of the five original case-control studies in BEACON and the data pooling methods for 
BEACON have been described in detail elsewhere.22,23 The remaining three case-control 
studies were recently added to the BEACON dataset, are included in this study, and have 
been described previously.11,20,21 In all studies, cases included persons with endoscopic 
evidence of columnar mucosa in the tubular esophagus, accompanied by the presence of 
specialized intestinal metaplasia in an esophageal biopsy, and cases included persons with 
prevalent and newly diagnosed BE.11,20-22 The cases are compared with population-based 
controls, that represent the underlying source population from which cases arose, and GERD 
controls, the population undergoing endoscopy from which BE cases are diagnosed. 
Population-based controls were frequency matched to BE cases on sex and age in 
most,16,18,19,21 but not all studies.11,20 GERD controls were matched to the BE group on age 
and sex in only two studies.18,21 The FINBAR study matched controls to their EA cases 
rather than BE cases.17 The original studies and the current data pooling were approved by 
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the institutional review board or research ethics committee of each sponsoring institution. 
Written informed consents were obtained from all study subjects.
For the current analysis, we excluded persons with missing data for waist and/or hip 
circumferences (431 population-based controls, 421 GERD controls and 236 BE cases). We 
additionally restricted our analyses to non-Hispanic white study participants (2557 
population-based controls, 2064 GERD controls, 1559 BE cases) due to low numbers of 
cases from non-white ethnic groups. Seven studies provided a population-based control 
group and six studies provided a GERD control group (Table 1).
Study variables
At interview, the following anthropometric measures were collected in-person using study-
specific protocols: height, weight, waist circumference, and hip circumference. In the Kaiser 
Permanente study, measurements of mid-thigh circumference were taken instead of hip 
circumference and used as a proxy for gluteofemoral obesity.18 As detailed below, for the 
analysis, we used study-specific tertiles to overcome the issue of differences in distributions 
between the included studies. Excluding Kaiser Permanente from the analysis did not 
change the results. We calculated body mass index (BMI) as weight in kilograms divided by 
height in meters squared (kg/m2). In addition to the anthropometric data, individual-level 
harmonized clinical, demographic, and questionnaire data for each study participant were 
merged into a single de-identified dataset and included information on study, case-control 
status, age at diagnosis for cases and age at study enrolment for controls, sex, ethnicity, 
highest level of education, frequency of GERD symptoms and history of cigarette smoking. 
Frequency of GERD symptoms was the highest reported frequency of either heartburn or 
acid regurgitation symptoms. We defined “frequent symptoms” as those occurring at least 
weekly. The data were checked for consistency and completeness and any apparent 
inconsistencies were followed-up with individual study investigators.
Statistical analysis
The primary aim of the analysis was to examine the associations of hip circumference and 
waist circumference (in tertiles and as a continuous measure) with the risk of BE, and then 
the effect of each measure after mutual adjustment with the risk of BE. Because distributions 
of anthropometric measures varied across studies and sexes, we derived study-and sex-
specific tertiles for hip and waist circumferences. We used a two-step analytic approach.24 In 
the first stage, study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were 
estimated using unconditional logistic regression models. In the second stage, the study-
specific ORs were combined using random-effects meta-analytic models to generate 
summary ORs. We excluded studies from the second-step if the logistic regression model 
failed to converge. We used the inconsistency index, I2, to assess heterogeneity between 
studies.25 Larger I2 values reflect increasing heterogeneity, beyond what is attributable to 
chance. I2 values of 25%, 50% and 75% were used as evidence of low, moderate, or high 
levels of heterogeneity, respectively.
Exposure variables were assessed in relation to risk of BE using population-based controls 
and GERD controls as comparison groups. Our approach was, first, to examine the 
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unadjusted associations of hip circumference and waist circumference with risk of BE. We 
then adjusted for age (<50, 50-<60, 60-<70, ≥70 years), sex, education (school only, 
technical college/diploma, university/college; unavailable and so unadjusted for in the 
University of North Carolina at Chapel Hill study), and smoking status (never, ever). Finally, 
we further mutually adjusted for hip and waist circumference to examine their independent 
effects on risk of BE. Models that compared cases with population-based controls were also 
subsequently adjusted for self-reported GERD symptoms (less than weekly vs. at least 
weekly) to evaluate potential confounding effects of GERD symptoms. The study-specific 
ORs for the Cleveland Barrett's Esophagus Study were unadjusted for education, smoking 
status and GERD symptoms due to unavailable data for these variables among population-
based controls. The lowest tertile for each categorical variable was used as the reference 
category. We evaluated continuous variables to test for linear trend by using OR per 5 cm 
increase in hip and waist circumference.
Finally, we assessed whether the association between hip circumference (and waist 
circumference) and risk of BE was modified by sex (male, female) by performing likelihood 
ratio tests of nested models with and without the hip circumference-sex interaction term. 
Likewise, but for comparisons with population-based controls only, we also assessed for 
effect modification by frequency of GERD symptoms (less than weekly, at least weekly).
All tests for statistical significance were two-sided at α=0.05 and analyses were conducted 
using Stata 13.1 (StataCorp LP, College Station, TX).
Results
The numbers of cases and controls, summary data for anthropometric measurements by 
study, and characteristics of the pooled dataset are shown in Tables 1 and 2. Cases and 
population-based controls were similar in terms of age and sex due to matching in most 
studies. There was considerable variation in average BMI, and waist and hip circumferences 
across the studies and case-control groups.
Table 3 shows the estimates of association between waist and hip circumferences and BE 
compared with both population-based controls and GERD controls. After adjusting for age, 
sex, education, and smoking status, waist circumference was positively associated with BE 
for comparisons with population-based controls (summary OR per 5cm increase = 1.08; 
95% CI: 1.01-1.15). After further adjustment for hip circumference, the magnitude of the 
association between waist circumference and BE was strengthened (vs. population-based 
controls: OR = 1.18; 95% CI: 1.06-1.31; Tertile 3 vs. Tertile 1, OR = 2.18; 95% CI: 
1.35-3.51, Ptrend<.001). While the association with waist circumference adjusted for hip 
circumference was somewhat attenuated when we compared cases with GERD controls, 
waist circumference remained statistically significantly associated with increased BE risk 
(OR = 1.09; 95% CI: 1.02-1.16).
In contrast, when compared with population-based controls, there was no association 
between hip circumference and BE in the unadjusted model or in the model adjusted for 
only age, sex, education, and smoking status (Table 3). However, after further adjustment for 
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waist circumference, we found an inverse association between hip circumference and BE for 
comparisons with population-based controls (OR = 0.88; 95% CI: 0.81-0.96). Compared to 
persons in the lowest tertile of hip circumference, persons in the highest tertile of hip 
circumference had 25% lower risk of BE (95% CI: 0.58-0.98, Ptrend = .04) in the mutually 
adjusted model (Supplementary Figure 1). We found no consistent association between hip 
circumference and BE when cases were compared with GERD controls (OR = 0.97; 95% 
CI: 0.87-1.08). For comparisons with population-based controls, the positive association 
with waist circumference (OR = 1.10; 95% CI: 1.01-1.21) and inverse association with hip 
circumference (OR = 0.89; 95% CI: 0.81-0.97) remained after additional adjustment for 
frequency of GERD symptoms (Supplementary Table 1).
When stratified by sex (Table 4), the strength of the association of waist circumference with 
BE was similar in males and females in the mutually adjusted population-based control 
model; although risk estimates for females did not reach statistical significant perhaps due to 
small numbers. We found no evidence for statistical interaction between waist circumference 
and sex in relation to risk of BE (Pinteraction = .10). However, hip circumference was 
inversely associated with BE in males in the mutually adjusted population-based control 
model (OR = 0.85; 95% CI: 0.76-0.96) but was not associated with BE in females (OR = 
0.93; 95% CI: 0.74-1.16; Pinteraction = .004). We additionally performed stratified analyses 
by GERD symptom history using the population-based control group as the comparator 
(Table 5). Waist circumference appeared to be more strongly associated with BE in those 
with infrequent GERD symptoms. The inverse association between hip circumference and 
BE was similar in magnitude in both those with infrequent and frequent GERD symptoms 
and frequency of GERD symptoms does not appear to modify the inverse association with 
hip circumference (Pinteraction = .62).
Among males within each category of waist circumference, larger hip circumference was 
associated with a decreased risk of BE (Supplementary Table 2). Males at the highest risk of 
BE simultaneously had waist circumference in the highest tertile and hip circumference in 
the lowest tertile. Males at the lowest risk of BE had waist circumference in the lowest tertile 
and hip circumference in the highest tertile. The pattern was different for females with hip 
circumference not reducing the risk of BE within each waist category; however, these 
analyses were limited by smaller numbers of females in all categories.
We found evidence for moderate to high between-study heterogeneity for associations 
between waist circumference and BE (Table 3). However, removal of the Cleveland Barrett's 
Esophagus Study reduced the between-study heterogeneity to below 10%. The association 
with waist circumference was somewhat attenuated as a result (ORTertile 2 = 1.37; 95% CI: 
1.08-1.74; I2 = 9%; ORTertile 3 = 1.68; 95% CI: 1.28-2.22; I2 = 4%). Likewise, there was 
evidence of low to moderate between-study heterogeneity for the association between hip 
circumference (continuous) and risk of BE (Table 3). This heterogeneity was mainly driven 
by a stronger inverse association from The Newly Diagnosed Barrett's Esophagus Study. 
When this study was excluded, I2 reduced from 42% to 20%. Importantly the effect estimate 
was only minimally attenuated and hip circumference remained inversely associated with 
BE (OR = 0.90; 95% CI: 0.83-0.98) when compared with population-based controls.
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Discussion
We conducted pooled analyses of eight case-control studies, examining the independent 
effects of abdominal obesity and gluteofemoral obesity on the risk of BE. As has been 
shown previously, we confirmed that abdominal obesity is associated with increased risk of 
BE. But in addition, we found that gluteofemoral obesity was inversely associated with BE. 
This association was strongest when we compared cases with population-based controls, and 
persisted even after adjusting for frequency of GERD symptoms. Finally, we found evidence 
of modification of the effect of gluteofemoral obesity by sex; the inverse association with 
hip circumference was statistically significant for analyses among males, but not in analyses 
among females.
In a prior cohort study, Steffen et al. found that gluteofemoral obesity was inversely 
associated with risk of EA, adjusting for abdominal obesity.10 However, that study was not 
able to adjust for potential confounding by GERD. In a prior case-control study, Rubenstein 
et al. found that gluteofemoral obesity was inversely associated with a combined outcome of 
BE or erosive esophagitis, adjusting for abdominal obesity, but the study was too small to 
accurately estimate the effect on BE alone, and did not include any females.11 
Gluteofemoral obesity has previously been shown to be protective against diabetes mellitus 
and cardiovascular disease.7,8
Adipose tissue in the gluteofemoral compartment behaves differently metabolically than 
adipose tissue in the abdominal compartment.7,9,26 It has been hypothesized that 
gluteofemoral adipose tissue may serve as a “metabolic sink” where excess calories can be 
safely stored without detrimental metabolic effects. Our finding of an inverse association of 
gluteofemoral obesity with the risk of BE suggests that abdominal obesity may not only 
exert its effects on risk via mechanical effects in promoting GERD but also via non-GERD 
metabolic effects. Multiple studies have demonstrated an association between levels of 
different circulating adipokines and BE or EA.5,21,27-29 It seems unlikely that a single factor 
is responsible for all of the risk attributable to obesity; rather it would seem that abdominal 
obesity (if not counteracted by gluteofemoral obesity) results in a milieu of circulating 
metabolic factors that promote BE and EA. Risk prediction models for BE that include a 
term for waist-to-hip ratio have been shown to have reasonable discriminatory ability;30,31 
whether gluteofemoral (hip circumference) and abdominal (waist circumference) obesity 
separately discriminate better between persons with and without BE than waist-to-hip ratio 
is unknown and requires further study.
Importantly, we found evidence for modification of the effect of gluteofemoral obesity by 
sex. There does not appear to be a protective effect among females. For unclear reasons, 
males are at much greater risk than females for BE,12 and especially for EA.32,33 Females 
and males differ in their distribution of adipose tissue, with males having over 50% greater 
intra-abdominal fat mass and a third less subcutaneous fat, including gluteofemoral fat, than 
females.34 In addition, estrogen regulates the secretion of adipokines from adipose tissue.35 
Taken together, these findings suggest that the differential compartments for deposition of 
adipose tissue and metabolic effects may explain much of the risk of male sex for BE.
Kendall et al. Page 7
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our study had some limitations. First, we were only able to study the outcome of BE and not 
EA. In EA nearly two-thirds of patients have substantial weight loss at diagnosis, making the 
study of obesity related factors difficult in case-control studies.36 In addition, the studies 
included a mix of patients with newly diagnosed and prevalent diagnoses of BE, which 
could have biased the results unpredictably. While we attempted to control for confounding, 
information on some known risk factors for BE (e.g. Helicobacter pylori status, diet, 
medication use) was not uniformly available across the studies, and it is possible that 
unmeasured (and/or unknown) variables might have influenced our results. Whether obesity 
(gluteofemoral and/or abdominal) affects risk of BE independently of GERD is further 
complicated in observational studies as it is impossible to exclude residual confounding by 
GERD because symptom history is imperfectly correlated with the occurrence of GERD, 
and reporting can be compromised by treatment history. Studies combining genetic and 
observational data are attempting to address this issue.37 We examined associations 
separately in males and females; however, even with the large resources of BEACON, the 
number of females in our study was still small and the risk estimates for females were 
imprecise as a result. Finally, there was moderate heterogeneity in some effect estimates. 
This between-study heterogeneity was largely driven by a single study. However, removal of 
the study only minimally attenuated the inverse association with hip circumference and risk 
of BE. While hip circumference was inversely associated with BE among persons with 
frequent GERD symptoms for comparisons with population-based controls, there was no 
association when we compared cases with GERD controls. There was however moderate to 
high between-study heterogeneity for these risk estimates, some of which may be due to 
differences between the individual study inclusion criteria for GERD controls.
There are also a number of strengths to the study. Notably, we were able to combine data 
from eight independent studies from different geographic regions. The component studies 
used a similar diagnosis of BE, and all measured anthropometrics rather than using self-
report. We were able to compare the effects to both population controls and GERD controls, 
adjust for a number of important potential confounders, and examine for effect modification 
by sex.
In summary, we found that while abdominal obesity is associated with increased risk of BE, 
gluteofemoral obesity is inversely associated with the risk of BE. The inverse association 
with gluteofemoral obesity is independent of GERD, and may not be present in females. 
These findings support a metabolic explanation for the effect of obesity on BE and for the 
risk of male sex on BE. Further studies are required to determine whether the distribution of 
obesity and metabolic effects promote the progression from BE to EA, and whether 
modifying these factors can prevent the cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used in this paper
BEACON Barrett's and Esophageal Adenocarcinoma Consortium
BMI body mass index
CI confidence interval
GERD gastroesophageal reflux disease
OR odds ratio
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Study population
We used data from eight independent case-control studies participating in BEACON: the 
Study of Digestive Health (based in Brisbane, Australia)16; the Factors Influencing the 
Barrett's/Adenocarcinoma Relationship (FINBAR) study (based in Ireland)17; the 
Epidemiology and Incidence of Barrett's Esophagus study (based in the Kaiser 
Permanente Northern California population)18; the Study of Reflux Disease (based in 
western Washington State)19; the Epidemiologic Case-Control Study of Barrett's 
Esophagus (based at The University of North Carolina at Chapel Hill, NC); the Houston 
Barrett's Esophagus study (based at the Michael E. DeBakey VA Medical Center at 
Houston, TX)20; The Newly Diagnosed Barrett's Esophagus Study (based at the 
University of Michigan and Ann Arbor Veterans Affairs Medical Center at Ann Arbor, 
MI)11, and the Cleveland Barrett's Esophagus Study (based at two hospitals in the Case 
Comprehensive Cancer Center at Cleveland, OH: University Hospitals Case Medical 
Center and Cleveland Clinic Foundation)21.
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Table 2
Characteristics of the Combined Study Population within the BEACON Consortium
BE cases
(n = 1559)
Population-based controls
(n = 2557)
GERD controls
(n = 2064)
Age, y, mean (SD) 60.0 (11.1) 58.2 (9.9) 57.3 (12.1)
Male sex, n (%) 1253 (80.4) 1839 (71.9) 1489 (72.1)
Education, n (%)
 School only 425 (28.9) 385 (21.1) 620 (37.0)
 Tech/Diploma 615 (41.7) 764 (41.8) 502 (29.9)
 University 433 (29.4) 677 (37.1) 555 (33.1)
 Missing 49 731 113
Smoking status, n (%)
 Never 489 (32.2) 760 (41.6) 779 (39.5)
 Ever 1030 (67.8) 1066 (58.4) 1192 (60.5)
 Missing 40 731 93
Frequency of GERD symptoms, n (%)
 Less than weekly 453 (31.0) 1355 (77.3) 686 (37.0)
 At least weekly 1009 (69.0) 399 (22.7) 1170 (63.0)
 Missing 97 803 208
NOTE. All population-based controls from Cleveland (n=707) were missing data for education, smoking status and frequency of GERD symptoms.
BE, Barrett's esophagus; GERD, gastroesophageal reflux disease; SD, standard deviation; y, years.
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